期刊文献+

基质金属蛋白酶1在扩张型心肌病大鼠中的表达特性 被引量:4

Expression of matrix metalloproteinase on dilated cardiomyopathy rat
原文传递
导出
摘要 目的探讨基质金属蛋白酶1(matrixmetalloproteinase,MMP1)在扩张型心肌病(DCM)大鼠中的表达特性。方法2周龄Wistar大鼠60只,雄性,体重(61.19±6.99)g,随机分为DCM组和空白对照(NC)组,每组又根据不同时间点分为4、8、12周3个亚组,利用呋喃唑酮诱导建立DCM模型。应用多功能超声心动图诊断仪检测不同时间点大鼠模型左室内径、左室射血分数(LVEF)及左室缩短率(LVFS)。苏木精伊红染色观察心肌组织的病理学改变。应用免疫组化方法检测Ⅲ型胶原含量的变化。应用RTPCR技术检测左室心肌MMP1的表达活性。结果DCM组4周、12周亚组大鼠的左室内径较NC组相应亚组明显增大(均P<0.01);DCM组3个亚组的LVFS及LVEF均较NC组相应亚组明显降低(4周,12周,均P<0.01,8周,P<0.05);DCM组12周亚组心脏重量/体重比值增加(P<0.05)。与NC组比较,DCM组各亚组大鼠心肌细胞肥大,胞质灶性溶解,呈不同程度的颗粒变性与空泡变性,细胞核增大、分裂、畸形,细胞间隙增宽,间质胶原纤维明显增生;心肌间质Ⅲ型胶原相对值明显增加(均P<0.01);心肌MMP1mRNA基因表达水平明显上升(4周,8周,均P<0.01,12周,P<0.05),但随着病程的发展有下调趋势。结论利用呋喃唑酮诱导建立大鼠DCM模型,为DCM的临床和实验研究提供理想的动物模型。 Objective:To detect the expression pattern of matrix metalloproteinase (MMP1 ) on dilated cardiomyopathy rat. Method: Sixty Wistar male rats, aged two weeks, body weight (~61.19 ±~6.99 )g in average, were studied randomly. All rats were divided into dilated cardiomyopathy model (DCM) group and normal control (NC) group, sub-divided into three group, 4-week sub-group, 8-week sub-group and 12-week sub- group, respectively. Echocardiography was used for the assessment of the left ventricular(LV) chamber dimensions, fractional shortening(FS)and ejection fraction(EF). The contents of collagen Ⅲ in the heart were determined by enzymoimmunohistochemincal staining. The myocardial pathological patterns were detected by HE staining. The expression patterns of MMP1 were detected using RT-PCR method. Result:The LV chamber dimensions in DCM group at 4W, 12W sub-group were increased significantly (P<~0.01 ) than that in NC group. The FS and EF in DCM group were decreased significantly (4 W, P<~0.01 , 8 W, P<~0.05 , respectively) than that in NC group. The HW/BW ratio in DCM group at 12 W sub-group was increased significantly (P<~0.05 ) than in NC group. Compared with NC group, there were much more significant cardiac myocyte hypertrophy accompanied with nucleus augmentation, differentiation and defferiation in the DCM group at all sub-group. Also, there were spot lysis, granular degeneration and vacuolation in the myocytic plasm at some degree. The intercellular space became larger where the myocardium interstitial collagen fibers were increased significantly. The comparative contents of the myocardium interstitial collagen Ⅲ were increased significantly (P<~0.01 ) in DCM group at all sub-group. The mRNA expression of MMP1 was increased significantly in DCM group (4 W, 8 W, P<~0.01 , 12 W, P<~0.05 , respectively), whereas down regulated during the developing time.Conclusion: The left ventricle dilates and LVM increases on DCM Wistar rat model induced by Furazolidone, which provides a powerful model for clinical and basic research on DCM. MMP1 involves in the left ventricular remodeling in this rat model.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2005年第4期230-233,共4页 Journal of Clinical Cardiology
基金 广西科学研究与技术开发攻关项目(No:桂科攻03220257)
关键词 心肌病 扩张型 基质金属蛋白酶1 Dilated cardiomyopathy Matrix metalloproteinase 1
  • 相关文献

参考文献8

  • 1郑兴,Yifei Huang,Stephen Hunyor.慢性缺血性心力衰竭时心肌基质金属蛋白含量的变化[J].临床心血管病杂志,2003,19(1):26-29. 被引量:10
  • 2Coker M L, Thomas C V, Clair M J, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol, 1998, 274: H1516-523.
  • 3Yuasa S, Nishia T, Nishimara K, et al. A rat model of dilated cardiomyopathy to investigate partial left ventriculetomy. J Card Surg, 2001, 16: 40-47.
  • 4Spinale F G, Krombach R S, Coker M L, et al. Matrix metalloproteinase inhibition during developing congestive heart failure: effects on left ventricular geometry and function. Circ Res, 1999, 85: 364-376.
  • 5Spinale F G, Coker M L, Thomas C V, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res, 1998, 82:482-495.
  • 6Spinale F G, Coker M L,Bond B R,et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart:a potential therapeutic target. Cardiovasc Res, 2000,46 : 225-238.
  • 7张怀勤,张恩光,徐力辛,李上共,黄伟剑,林捷.基质金属蛋白酶对大鼠心肌梗死后心室重塑的影响[J].中华心血管病杂志,2003,31(3):223-225. 被引量:8
  • 8Rouet-Benzineb P, Buhler J M, Dreyfus P, et al. Altered balance between matrixgelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation .Eur J Heart Fail,1999,1 :337-352.

二级参考文献21

  • 1[1]Cleutjens J P M. The role of matrix metalloproteinases in heart failure. Cardivas Res, 1996,32:816-821.
  • 2[2]Cleutjens J P M, Kandala J C, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol, 1995, 27: 1281-1292.
  • 3[3]Spinale F G, Coker M L, Thomas C V, et al. Time-dependent changes in matrix metalloproteinase activity during the progression of congestive heart failure. Relative to ventricular and myocyte function. Cir Res, 1998,82:482-495.
  • 4[4]Thomas C V, Coker M L, Zellner J L, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1998,97:1708-1715.
  • 5[5]Huang Y F, Kawaguchi O, Zeng B, et al. A stable ovine congestive heart failure model. A suitable substrate for left ventricular assist device assessment. ASAIO J, 1997,43:M408-413.
  • 6[6]Mann D L, Spinalae F G. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that bands. Circulation, 1998,98:1699-1702.
  • 7[7]Coker M L, Thomas C V, Clair M J, et al. Myocardial matrix metallotroteinases activity and aboundance with congestive heart failure. Am J Pathol, 1998,274(5 Pt 2): H1516-1523.
  • 8[8]Gilbert S J, Wotton P R, Tarlton J F, et al. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res, 1997,34:377-383.
  • 9[9]Tyagi S I,Kumar S G, Haas S J, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol, 1996,28:1415-1428.
  • 10[10]Li YY, Feldman A M, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinase in the failing human heart. Circulation, 1998,98:1728-1734.

共引文献16

同被引文献56

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部